Infusion Pumps Market Reaches USD 12.28 Billion in 2026, Driven by Rising Prevalence of Chronic Diseases and Growing Demand for Controlled Drug Delivery

Technological Advancements and Enhanced Safety Features to Drive Infusion Pumps Market to USD 21.88 Billion by 2033 at an 8.6% CAGR – Coherent Market Insights

The Infusion Pumps Market, estimated at USD 12.28 Bn in 2026, is expected to exhibit a CAGR of 8.6% and reach USD 21.88 Bn by 2033.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Large volume infusion pump segment held dominant position in the global infusion pump market in 2026, accounting for 27.2% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.

Market Trends

Increasing number of surgical procedures is one of the key trends expected to boost the growth of the global infusion pump market. Infusion pumps play a key role in drug administration in surgical patients; are of significant concern to anesthesiologists. Infusion pump, such as elastomeric pumps, are used to administer liquid drugs such as local anesthetics, analgesics, cytostatics, or antibiotics (depending on the therapy). They are designed for continuous drug delivery, on-demand delivery, or combination of both continuous and on-demand drug delivery. Thus, with the increasing number of surgical procedures, the use or demand for infusion pumps is also increasing rapidly. This trend is expected to continue during the forecast period.

Competitive Landscape

Major players operating in the global infusion pump market include BD, Fresenius Kabi, ICU Medical, Smiths Medical, Medtronic, and B. Braun Melsungen, among others.

Recent Developments

• In March 2026, MiniMed received U.S. FDA clearance for MiniMed Flex, its smallest and first smartphone-controlled insulin pump. About half the size of the MiniMed 780G, the screenless device uses the SmartGuard adaptive algorithm with Meal Detection technology to automatically adjust insulin delivery. It includes a 300-unit reservoir, supports Simplera Sync and Abbott’s Instinct sensors, and works with infusion sets offering up to seven days of wear for greater convenience. (Source: MiniMed)
• In February 2026, Portal Diabetes received FDA Breakthrough Device Designation for its investigational implantable Portal Pump. Designed for intraperitoneal insulin delivery, the system aims to provide faster insulin action and more closely mimic natural pancreatic function. Portal plans a fully closed-loop platform integrated with continuous glucose monitoring, with office-based insulin refills every six to twelve weeks. Clinical trials in patients are expected to begin in the fourth quarter of 2027.
• In January 2026, ICU Medical received Health Canada clearance for its Plum Solo and Plum Duo precision IV pumps with LifeShield infusion safety software. The single- and dual-channel systems deliver ±3% accuracy and are designed to reduce infusion variability across care settings. Featuring full-colour touchscreens, centralized software updates, and IV-EHR interoperability, the devices expand ICU Medical’s IV Performance Platform and support safer, more consistent medication delivery in Canadian hospitals nationwide. (Source: ICU Medical)
• In July 2026, Tandem Diabetes Care launched t X2 insulin pump compatibility with Abbott’s FreeStyle Libre 3 Plus sensor in the United Kingdom, Switzerland, Sweden, Finland, and Italy. The integration pairs Control-IQ+ automated insulin delivery technology with a sensor offering up to 15 days of wear and minute-by-minute glucose readings. Tandem plans further expansion into Belgium, the Netherlands, and Germany during 2026, broadening connected diabetes-management options for insulin pump users. (Source: Tandem Diabetes Care)